Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Teucrium Wheat Fund — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.22 (market cap $2.27B), while Teucrium Wheat Fund trades at $24.82 (market cap $273.67M). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 8.3× Teucrium Wheat Fund's market cap, and Teucrium Wheat Fund is more actively traded (222,576 versus 4,179,659). Which is the better fit depends on your goals.
| SLS | WEAT | |
|---|---|---|
Market Cap | $2.27B | $273.67M |
Volume | 4,179,659 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $15.46 | $28.00 |
52-Week Low | $1.39 | $19.88 |
Enterprise Value | $2.14B | — |
Typical Hold Time | — | 40 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WEAT trades at $24.9, down 2.31% over the past day amid a bearish technical signal from moving averages. The stock's technical indicators show neutral oscillators but selling pressure from the ADX. Recent news highlights WEAT's strong performance earlier in the year, with a 25% year-to-date gain as of July 2026, though inflation concerns persist as a market-wide theme.
The outlook for WEAT is cautious due to bearish technical momentum and macroeconomic headwinds from inflation. Investment opportunity exists if the stock holds key support levels, but risks include continued selling pressure and sensitivity to broader economic conditions. Investors should weigh technical weakness against the fund's earlier 2026 gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
